Department of Nuclear Medicine, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka, Saitama, 350-1298, Japan.
Neuroimaging Clin N Am. 2012 Feb;22(1):57-65, viii. doi: 10.1016/j.nic.2011.11.005. Epub 2011 Dec 6.
This article reviews current amyloid positron emission tomography (PET) imaging with particular attention to Pittsburgh compound-B (PiB), the most extensively investigated and validated tracer. PiB specifically binds to fibrillar β-amyloid deposits such as those found in the cerebral cortex and striatum. PiB-PET imaging is a sensitive and specific biologic marker for underlying amyloid deposition, which is an early event on the path to dementia. Amyloid imaging in healthy controls and patients with mild cognitive impairment may detect those at high risk of future Alzheimer's disease, identifying them as candidates for early preventive measures if and when they become available.
本文回顾了当前的淀粉样蛋白正电子发射断层扫描（PET）成像，特别关注匹兹堡化合物-B（PiB），这是研究和验证最广泛的示踪剂。PiB 特异性结合纤维状 β-淀粉样蛋白沉积物，如大脑皮层和纹状体中发现的沉积物。PiB-PET 成像 是潜在淀粉样蛋白沉积的敏感和特异性生物标志物，淀粉样蛋白沉积是痴呆发生的早期事件。在健康对照者和轻度认知障碍患者中进行淀粉样蛋白成像可以发现那些未来发生阿尔茨海默病风险较高的患者，如果将来有预防措施，就可以将他们确定为早期预防措施的候选者。
